CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Phase 3AspireNeutral
AI Analysis

Summary

Ultragenyx announced Phase 3 Aspire trial results for its Angelman Syndrome treatment. The article title indicates a data readout but lacks specific efficacy, safety, or outcome details.

Clinical Trial Data

Phase

Phase 3

Importance:7/10
Sentiment:
0.00
Phase 3Angelman Syndromerare diseaseclinical trial results
Related Companies

Read the original article

Published by yahoo_finance on September 2, 2026 8:01 PM

Read Original